4DCT oesophageal tumour delineation in SCOPE2 – how is radiotherapy quality assurance beneficial?
4DCT scanning in radiotherapy (RT) planning for distal oesophageal cancer enables the generation of patient specific target volumes by accounting for tumour motion. UK experience of this technique is increasing, facilitated by robust RT trial quality assurance (RTTQA) programmmes. We present outcome...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Conference item |
| Published: |
Elsevier
2018
|
| _version_ | 1826261188274552832 |
|---|---|
| author | Cox, S Jones, G Radhakrishna, G Mukherjee, S Hawkins, M Crosby, T Gwynne, S |
| author_facet | Cox, S Jones, G Radhakrishna, G Mukherjee, S Hawkins, M Crosby, T Gwynne, S |
| author_sort | Cox, S |
| collection | OXFORD |
| description | 4DCT scanning in radiotherapy (RT) planning for distal oesophageal cancer enables the generation of patient specific target volumes by accounting for tumour motion. UK experience of this technique is increasing, facilitated by robust RT trial quality assurance (RTTQA) programmmes. We present outcomes to date of 4DCT RTTQA within the Study of Chemoradiotherapy in Oesophageal cancer including PET response and dose Escalation (SCOPE2), a currently recruiting phase II/III trial. |
| first_indexed | 2024-03-06T19:17:35Z |
| format | Conference item |
| id | oxford-uuid:18efbbb1-f4af-4426-9117-c898333a8923 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T19:17:35Z |
| publishDate | 2018 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:18efbbb1-f4af-4426-9117-c898333a89232022-03-26T10:46:05Z4DCT oesophageal tumour delineation in SCOPE2 – how is radiotherapy quality assurance beneficial?Conference itemhttp://purl.org/coar/resource_type/c_5794uuid:18efbbb1-f4af-4426-9117-c898333a8923Symplectic Elements at OxfordElsevier2018Cox, SJones, GRadhakrishna, GMukherjee, SHawkins, MCrosby, TGwynne, S4DCT scanning in radiotherapy (RT) planning for distal oesophageal cancer enables the generation of patient specific target volumes by accounting for tumour motion. UK experience of this technique is increasing, facilitated by robust RT trial quality assurance (RTTQA) programmmes. We present outcomes to date of 4DCT RTTQA within the Study of Chemoradiotherapy in Oesophageal cancer including PET response and dose Escalation (SCOPE2), a currently recruiting phase II/III trial. |
| spellingShingle | Cox, S Jones, G Radhakrishna, G Mukherjee, S Hawkins, M Crosby, T Gwynne, S 4DCT oesophageal tumour delineation in SCOPE2 – how is radiotherapy quality assurance beneficial? |
| title | 4DCT oesophageal tumour delineation in SCOPE2 – how is radiotherapy quality assurance beneficial? |
| title_full | 4DCT oesophageal tumour delineation in SCOPE2 – how is radiotherapy quality assurance beneficial? |
| title_fullStr | 4DCT oesophageal tumour delineation in SCOPE2 – how is radiotherapy quality assurance beneficial? |
| title_full_unstemmed | 4DCT oesophageal tumour delineation in SCOPE2 – how is radiotherapy quality assurance beneficial? |
| title_short | 4DCT oesophageal tumour delineation in SCOPE2 – how is radiotherapy quality assurance beneficial? |
| title_sort | 4dct oesophageal tumour delineation in scope2 how is radiotherapy quality assurance beneficial |
| work_keys_str_mv | AT coxs 4dctoesophagealtumourdelineationinscope2howisradiotherapyqualityassurancebeneficial AT jonesg 4dctoesophagealtumourdelineationinscope2howisradiotherapyqualityassurancebeneficial AT radhakrishnag 4dctoesophagealtumourdelineationinscope2howisradiotherapyqualityassurancebeneficial AT mukherjees 4dctoesophagealtumourdelineationinscope2howisradiotherapyqualityassurancebeneficial AT hawkinsm 4dctoesophagealtumourdelineationinscope2howisradiotherapyqualityassurancebeneficial AT crosbyt 4dctoesophagealtumourdelineationinscope2howisradiotherapyqualityassurancebeneficial AT gwynnes 4dctoesophagealtumourdelineationinscope2howisradiotherapyqualityassurancebeneficial |